10.1200/JCO.2023.41.6_suppl.166 Journal of Clinical Oncology 41, no. 6_suppl (February 20, 2023) 166-166.
Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study / Gennusa, Vincenzo; Saieva, Calogero; Lee-Ying, Richard M.; Nuzzo, Pier Vitale; Spinelli, Gian Paolo; Zanardi, Elisa; Fotia, Giuseppe; Rossetti, Sabrina; Valenca, Loana Bueno; Patrikidou, Anna; Andrade, Livia; Pereira Mestre, Ricardo; Fornarini, Giuseppe; Procopio, Giuseppe; Santini, Daniele; Sweeney, Christopher; Heng, Daniel Yick Chin; De Giorgi, Ugo; Russo, Antonio; Francini, Edoardo. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - ELETTRONICO. - 41:(2023), pp. 166-166. [10.1200/JCO.2023.41.6_suppl.166]
Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study
Francini, Edoardo
Conceptualization
2023
Abstract
10.1200/JCO.2023.41.6_suppl.166 Journal of Clinical Oncology 41, no. 6_suppl (February 20, 2023) 166-166.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
